BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. The company is headquartered in Modiin, Central(Hamerkaz) and currently employs 24 full-time employees. The company went IPO on 2007-01-30. The firm is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The firm is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
BLRX stock price ended at $3.02 on 星期三, after dropping 0.98%
On the latest trading day Jun 17, 2026, the stock price of BLRX fell by 0.98%, dropping from $3.05 to $3.02. During the session, the stock saw a volatility of 11.71%, with prices oscillating between a daily low of $2.99 and a high of $3.34. On the latest trading day, the trading volume for BLRX rose by 1.6K shares, despite the declining prices. This uptick in volume may signal heightened risk in the near term. In total, 12.7K shares were traded, with a market value of approximately $13.1M.